Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction.
The electrophysiologic effects of intravenously administered disopyramide (2 mg/kg) on three parameters of sinus node function were examined in 16 symptomatic patients with sinus node dysfunction. Based on their ECG data before study, patients were subdivided into group A (n = 8), those with sinus pauses and/or sinoatrial (SA) exit block; and group B (n = 8), those with sinus bradycardia. Disopyramide shortened spontaneous cycle length in 10 of 16 patients and lengthened it in six--markedly so (91%) in one patient. Estimated SA conduction time decreased in seven of 14 patients and increased in seven. Two patients developed second degree SA exit block after disopyramide. Maximum sinus node recovery time was prolonged by disopyramide in 11 of 16 patients and markedly so in four. For the group as a whole there was no significant difference in spontaneous cycle length, maximum sinus node recovery time or estimated SA conduction time. P-wave and QRS durations and H-V intervals were significantly lengthened by disopyramide. Marked depression of the three parameters of sinus node function occurred in three group A patients and in one group B patient who had persistent severe sinus bradycardia. These four patients also had secondary pauses after termination of rapid atrial pacing under control conditions. Disopyramide should be administered cautiously to patients with sinus node dysfunction, particularly those with sinus pauses, SA exit block or secondary pauses.
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000139:chemically induced; D001283:Atrioventricular Node / Q000187:drug effects / Q000503:physiopathology; D001919:Bradycardia / Q000188:drug therapy / Q000503:physiopathology; D002304:Cardiac Pacing, Artificial; D004206:Disopyramide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006327:Heart Block / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D012848:Sinoatrial Block / Q000188:drug therapy* / Q000503:physiopathology; D012849:Sinoatrial Node / Q000187:drug effects* / Q000503:physiopathology; D013610:Tachycardia / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors
D011725:Pyridines; D004206:Disopyramide